Correlation Heatmap. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Immune Cell Correlation Analysis. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

GO Enrichment Analysis. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Differential Analysis. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

GO Diagram. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Hub Genes. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

PPI. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Download Data. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Heatmap. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Figure 2. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

KEGG Enrichment Analysis. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Figure 1. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Gene Name to ID Conversion. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Bar Chart. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Filter Samples with p < 0.05. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

KEGG Diagram. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Grouping and Sorting. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Violin Plot. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

XCell Algorithm for Immune Cell Matrix. by Guolian Wu (21464168)

“…These findings provide potential diagnostic biomarkers and therapeutic targets for KD, warranting further validation in larger studies.</p></div>…”

Data Sheet 1_Treatment with pemafibrate ameliorates fatty liver index and atherogenic lipid profiles in Japanese patients with type 2 diabetes mellitus.pdf by Toru Suzuki (512729)

“…FLI (mean ± standard deviation: 68.1 ± 21.9 vs. 39.6 ± 25.0, P < 0.001), but not FIB-4 index as a marker of hepatic fibrosis (median [interquartile range]: 1.04 [0.78-1.39] vs. 1.01 [0.68-1.36], P = 0.909), was significantly decreased by treatment with pemafibrate for 12M, and the proportion of patients with metabolic dysfunction-associated SLD (MASLD) was significantly decreased from 92.3% (baseline) to 61.5% (12M).…”